X4 PharmaceuticalsNASDAQ: XFOR

X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is targeting rare diseases with mavorixafor, approved for WHIM syndrome, and moving forward with a Phase III trial for CN. X4 Pharmaceuticals has the potential for significant growth with mavorixafor addressing multiple rare diseases, but faces risks including FDA approval and market penetration.

Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia

X4 Pharmaceuticals announced on Monday that the drug for a rare genetic immunodeficiency disease has been approved by the U.S. FDA.

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, 2023 and providing corporate updates on Thursday, March 21, 2024.

X4 Pharmaceuticals has dipped considerably following updated results presented in ASH suggesting that mavorixafor may not be effective as monotherapy in chronic neutropenia (excluding WHIM). Mavorixafor will likely still have a role in chronic neutropenia as add-on to G-CSF. Mavorixafor can enable reductions in G-CSF dosing, which can improve tolerability and is meaningful for patients. FDA has granted priority review for mavorixafor in WHIM, with a PDUFA date of April 30, 2024, and a potential PRV worth $100M upon approval.

BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in fireside chats at the upcoming Stifel Healthcare Conference being held in New York City, from November 14-15, 2023, and the Piper Sandler 35th Annual Healthcare Conference being held in New York City, from November 28-30, 2023.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Paula Ragan – Chief Executive Officer Mark Baldry – Chief Commercial Officer Christophe Arbet-Engels – Chief Medical Officer Adam Mostafa – Chief Financial Officer Conference Call Participants Eva Privitera – TD Cowen Stephen Willey – Stifel Edward Tenthoff – Piper Sandler Andy Fleszar – B. Riley Securities Kristen Kluska – Cantor Fitzgerald Swayampakula Ramakanth – H.C.

BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the second quarter ended June 30, 2023, and providing corporate and clinical program updates on Thursday, August 10, 2023.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Dr. Paula Ragan - President and CEO Adam Mostafa - CFO Mark Baldry - Chief Commercial Officer Conference Call Participants William Wood - B. Riley Securities Eva Privitera - TD Cowen Swayampakula Ramakanth - Wainwright Rick Miller - Cantor Fitzgerald Operator Greetings, and welcome to X4 Pharmaceuticals' First Quarter 2023 Earnings Conference Call.